Overview

Evaluation of ETC-1002 vs Placebo in Patients Receiving Ongoing Statin Therapy

Status:
Completed

Trial end date:
2015-01-01

Target enrollment:

Participant gender:

Summary

The purpose of this research study is to see how ETC-1002 is tolerated in the body and how ETC-1002 affects the levels of LDL-C (bad cholesterol) in patients receiving ongoing statin therapy.

Phase:

Phase 2

Details

Lead Sponsor:

Esperion Therapeutics
Esperion Therapeutics, Inc.

Collaborator:

Medpace, Inc.

Treatments:

8-hydroxy-2,2,14,14-tetramethylpentadecanedioic acid
Hydroxymethylglutaryl-CoA Reductase Inhibitors